The promise of DDR kinases as a therapeutic target has been demonstrated by DDR1 knockdown that has been shown to reduce metastatic activity in lung cancer models [22], slow the development of atherosclerosis [13] and impede the development of fibrotic disorders [23–25]. This evidence concerns the gene DDR1 and lung carcinoma.